diabetic retinopathy
Conditions
Interventions
1:conbercept injection after surgery
2:no injection after surgery
Sponsors
Eye and ENT hospital, Fudan University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. signed the informed consent, and is willing to follow up according to the time stipulated in the test; 2. aged 18~70 years old; 3. target eyes must meet the following requirements: PDR surgical indications: 1) persist (1-3 months) vitreous hemorrhage; 2) TRD or RRD involved macular or threatened macula; 3) vitreous retinal adhesions caused by fibrous proliferation; vision 20/40 - HM/BE; HbA1c < 8% Note: if both of the patient's eyes met the inclusion criteria, the investigator identified the target eye from the medical angle.
Exclusion criteria
Exclusion criteria: 1. target eye has a history of vitrectomy surgery, or in this experiment, silicone oil was filled after surgery, or had been filled with gas or silicone oil for less than 6 months; 2. patients with uncontrollable hypertension (defined as after treatment, blood pressure is still greater than 150/95 mmHg); 3. coagulation function abnormity or recently (3 months) use anticoagulant medication, if aspirin is required to be stopped within 1 week before operation; 4. had an eye disease history of non-diabetic VH; 5. had received anti-VEGF treatment within 3 months and systemic anti-VEGF drugs were used within 6 months; 6. target eyes underwent eye surgery within 6 months; 7. target eyes were resected after the first vitreous surgery due to non-VH retinal disease; 8. systemic arterial thrombosis events such as cerebral apoplexy, myocardial infarction, etc.; 9. target eye infection (e.g. blepharitis, infectious conjunctivitis, keratitis, sclera, endophthalmitis) or repeated infection; 10. uncontrolled glaucoma (defined as the intraocular pressure after glaucoma treatment still > 25 mmHg), or optic disc ratio > 0.8, or target eyes underwent glaucoma filtration surgery; 11. aphakic (excluding intraocular lens) or posterior capsular rupture (except YAG laser after intraocular lens implantation); 12. tumor; 13. allergic to fluorescein sodium, allergic disease; 14. a history of surgery within one month and/or there were currently unhealed wounds, ulcers, fractures, etc. 15. affected by infectious diseases; 16. any uncontrolled clinical problems (such as HIV/AIDS, malignant tumor, active hepatitis, renal failure, serious mental, nervous, cardiovascular and respiratory system diseases, etc.); 17. has previously used drugs that may cause nephrotoxicity, including chloroquine, hydroxychloroquine, phenothiazine, chlorpromazine, thiopyridazine, fluorphenazine, perphenazine, and trifluorazine; 18. did not use effective contraceptives; Note: the following situations are not excluded. (1) In natural conditions, the level of the serum follicle stimulating hormone was 3 months, for five half-life) taken part in clinical trials of any drugs (not including vitamins and minerals); 21. researchers believe that they need to be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence of vitreous hemorrhage after operation;Time of clearance vitreous hemorrhage after operation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Best corrected visual acuity; | — |
Countries
China
Contacts
Public ContactChang Qing
Eye and ENT hospital, Fudan University
Outcome results
None listed